Corvus Pharmaceuticals, Inc. (CRVS)
CRVS moved a median of -0.32% 30 minutes after news, and -1.06% by the close. How CRVS actually reacts to news — the realized, point-in-time move the market made, measured across 208 labeled events over the last three years with zero look-ahead.
CRVS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 208 |
| 30-min | -0.32% | 48% | 208 |
| 60-min | +0.04% | 51% | 208 |
| to close | -1.06% | 41% | 208 |
| Middle 50% of CRVS reactions | -3.19% to +2.13% |
|---|---|
| Median reaction (30-min) | -0.32% |
| Measured reactions | 208 |
Half of all Corvus Pharmaceuticals, Inc. news events land between -3.19% and +2.13% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CRVS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CRVS's baseline. Nothing else.
Recent CRVS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa | Press release | GlobeNewswire | +0.22% | -5.45% | |
| Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference | Press release | GlobeNewswire | -1.39% | +1.88% | |
| Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial | Press release | GlobeNewswire | +0.27% | -0.14% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +4.76% | +8.66% | |
| Form 10-Q Corvus Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.76% | +8.66% | |
| Form 8-K Corvus Pharmaceuticals, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +4.76% | +8.66% | |
| Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 | Press release | GlobeNewswire | -0.68% | +0.15% | |
| Form 8-K Corvus Pharmaceuticals, For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | +0.29% | |
| Form 8-K Corvus Pharmaceuticals, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +2.42% | -0.92% | |
| Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China | Press release | GlobeNewswire | +1.47% | -0.62% | |
| Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | +0.20% | +5.91% | |
| Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting | Press release | GlobeNewswire | -5.16% | -13.03% | |
| Form 8-K Corvus Pharmaceuticals, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -5.16% | -13.03% | |
| Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +2.97% | +5.00% | |
| Form 10-Q Corvus Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.97% | +5.00% | |
| Form 8-K Corvus Pharmaceuticals, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +2.97% | +5.00% | |
| Form S-8 Corvus Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +2.97% | +5.00% | |
| Form DEF 14A Corvus Pharmaceuticals, For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +2.39% | -0.99% | |
| Form DEFA14A Corvus Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +2.39% | -0.99% | |
| Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors | Press release | GlobeNewswire | +2.14% | -7.24% | |
| Form 8-K Corvus Pharmaceuticals, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +0.44% | |
| Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting | Press release | GlobeNewswire | +3.21% | +10.15% | |
| Form 8-K Corvus Pharmaceuticals, For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | +2.73% | -1.42% | |
| Form S-3ASR Corvus Pharmaceuticals, | SEC filing · Form S-3ASR | SEC EDGAR | +2.73% | -1.42% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +2.73% | -1.42% | |
| Form 10-K Corvus Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.73% | -1.42% | |
| Form 8-K Corvus Pharmaceuticals, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +2.73% | -1.42% | |
| Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 | Press release | GlobeNewswire | -1.51% | -0.91% | |
| Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +3.91% | +3.91% | |
| Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M | Press release | GlobeNewswire | -4.29% | -4.13% | |
| Form 8-K Corvus Pharmaceuticals, For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | +0.70% | -1.80% | |
| Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock | Press release | GlobeNewswire | +5.60% | +5.02% | |
| Form S-3MEF Corvus Pharmaceuticals, | SEC filing · Form S-3MEF | SEC EDGAR | +5.60% | +5.02% | |
| Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Press release | GlobeNewswire | +2.67% | +58.48% | |
| Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +6.04% | +2.12% | |
| Form 8-K Corvus Pharmaceuticals, For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +2.67% | +58.48% | |
| Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Press release | GlobeNewswire | +2.67% | +58.48% | |
| Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference | Press release | GlobeNewswire | -2.55% | -6.34% | |
| Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial | Press release | GlobeNewswire | +0.11% | -5.93% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +3.91% | -0.13% | |
| Form 10-Q Corvus Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.91% | -0.13% | |
| Form 8-K Corvus Pharmaceuticals, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +3.91% | -0.13% | |
| Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition | Press release | GlobeNewswire | -2.79% | -2.66% | |
| Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference | Press release | GlobeNewswire | -2.06% | +3.61% | |
| Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 | Press release | GlobeNewswire | -0.90% | -0.78% | |
| Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 | Press release | GlobeNewswire | -1.59% | -6.51% | |
| Corvus Pharmaceuticals Appoints David Moore to Board of Directors | Press release | GlobeNewswire | +1.56% | +2.13% | |
| Form 8-K Corvus Pharmaceuticals, For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | +2.13% | |
| Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -1.19% | +2.86% | |
| Form 10-Q Corvus Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.19% | +2.86% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CRVS section they belong to.
Where else CRVS is measured.
CRVS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Amarin Corporation plc - American Depositary Shares (AMRN) | 211 | +0.30% | 55% |
| BioRestorative Therapies, Inc. (BRTX) | 209 | -0.82% | 38% |
| Journey Medical Corporation (DERM) | 208 | 0.00% | 50% |
| Windtree Therapeutics, Inc. (WINT) | 207 | -1.40% | 27% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Corvus Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled CRVS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 208 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of CRVS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CRVS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.